ACTRN12617000756325已完成未知
The impact of ImpACT: Validation of an accelerated diagnostic protocol for Aboriginal and Torres Strait Islander patients presenting to an Emergency Department with suspected Acute Coronary Syndrome.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 271
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Patients will be included if they are aged 18 years and above, identify as Aboriginal and/or Torres Strait Islander, have presented to the Cairns Hospital Emergency Department and:
- •2.Present with symptoms of 5 minutes or more in duration consistent with possible ACS such as chest discomfort or angina equivalent; AND/OR; Physicians plan to evaluate the patient for suspected ACS
排除标准
- •Patients will be excluded from the research study if:
- •1. They are pregnant
- •2. Aged less than 18 years old
- •3. A clear alternative non-ACS diagnostic cause for symptoms is determined
- •4. The researcher feels that recruitment is inappropriate (e.g. Terminal illness)
- •5. The patient (or legal representative) is unable or unwilling to provide informed consent
- •6. Patient (or legal representative) refusal of telephone follow up or medical record review at 30 days or unlikely to be contactable e.g. they will be overseas
- •7. The patient has been transferred from another hospital with sensitive troponin testing commenced at referring facility
- •8. The patient has been recruited to the trial within the last 30 days.
研究者
相似试验
招募中
Unknown
SW Government-Sponsored Clinical Trial: Extended supply of Oral Contraceptive Pills (OCPs) by Community PharmacistsOral ContraceptionReproductive Health and Childbirth - ContraceptionPublic Health - Health service researchACTRN12623001124628The University of Newcastle88,000
进行中（未招募）
不适用
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary HyperparathyroidismEstudio IMPACT: Estudio para evaluar la mejora en el control de la hormona paratiroidea intacta (PTHi) mediante terapia basada en Paricalcitol frente a Cinacalcet con dosis bajas de Vitamina D en sujetos en hemodiálisis con hiperparatiroidismo secundario. - IMPACT SHPTSecondary hyperparathyroidism (SHPT)Hiperparatiroidismo secundarioMedDRA version: 12.0Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryMedDRA version: 12.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2009-011378-14-ESAbbott GmbH & Co. KG248
进行中（未招募）
不适用
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism. - IMPACT SHPTSecondary hyperparathyroidism (SHPT).MedDRA version: 9.1Level: LLTClassification code 10020708MedDRA version: 9.1Level: PTClassification code 10020708EUCTR2009-011378-14-ITAbbott GmbH & Co. KG248
进行中（未招募）
不适用
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism - IMPACT SHPTSecondary hyperparathyroidism (SHPT)MedDRA version: 12.0Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryMedDRA version: 12.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2009-011378-14-GRAbbott GmbH & Co. KG248
进行中（未招募）
不适用
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism - IMPACT SHPTSecondary hyperparathyroidism (SHPT)MedDRA version: 12.0Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryMedDRA version: 12.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2009-011378-14-PTAbbott GmbH & Co. KG248